Lymphoma, Follicular
|
0.400 |
Biomarker
|
disease |
BEFREE |
Arguably the MYC activity gain is the most constantly observed phenomenon (>70% of cases) in transformed FL/MALT/CLL (Richter's transformation) and co-occurs with specific aberrations such as the loss of p53, CDKN2A/B, or gain of BCL2/BCL6.
|
31631728 |
2020 |
Lymphoma, Follicular
|
0.400 |
Biomarker
|
disease |
BEFREE |
Focusing on low-grade FL versus MZL, MEF2B was 100% sensitive and 95% specific for FL, which was similar to BCL6, but superior to LMO2 (sensitivity 87%, specificity 86%) and HGAL (sensitivity 97%, specificity 86%).
|
29309299 |
2018 |
Lymphoma, Follicular
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Double-hit follicular lymphomas seemed to be a different disease from high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements and have an indolent clinical behavior similar to follicular lymphomas without MYC rearrangement.
|
28984304 |
2018 |
Lymphoma, Follicular
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The most common scenario is transformation of follicular lymphoma to either diffuse large B-cell lymphoma or high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 translocations; however, other indolent subtypes such as marginal zone lymphoma, lymphoplasmacytic lymphoma, small lymphocytic lymphoma/chronic lymphocytic leukemia, or even nodular lymphocyte predominant Hodgkin lymphoma, can undergo similar histologic transformation.
|
30213394 |
2018 |
Lymphoma, Follicular
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Fluorescent in situ hybridization detected IGH/BCL2 translocation in 1 FL, increased BCL6 copy number in another FL, BCL6 rearrangement, and increased copy number of MYC and MALT1 in the DLBCL with marginal zone lymphoma.
|
28038709 |
2017 |
Lymphoma, Follicular
|
0.400 |
Biomarker
|
disease |
BEFREE |
Integrative genomics and functional studies of BCL6 in primary FL cells point toward a novel mechanism whereby BCL6 repression of <i>NOTCH2</i> drives the survival and growth of FL cells as well as GC B cells, which are the FL cell of origin.<i>Cancer Discov; 7(5); 506-21.
|
28232365 |
2017 |
Lymphoma, Follicular
|
0.400 |
Biomarker
|
disease |
BEFREE |
To characterize PCFL and PCMZL more clearly and to define criteria helpful for the differential diagnosis, we compared expression of immunohistochemical markers [LIM-only transcription factor 2 (LMO2), human germinal centre-associated lymphoma (HGAL), stathmin 1 (STMN1), activation-induced cytidine deaminase (AID), myeloid cell nuclear differentiation antigen (MNDA)] and the presence of cytogenetic abnormalities described previously in nodal follicular lymphoma [B cell lymphoma 2 (BCL2) and BCL6 breaks, 1p36 chromosomal region deletion (del 1p36)] in a series of 48 cutaneous follicular and marginal zone lymphomas [cutaneous follicular lymphoma (CFL) and cutaneous marginal zone lymphoma (CMZL)].
|
28594133 |
2017 |
Lymphoma, Follicular
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We also found transcription factors (TF) whose binding may be disturbed by these mutations in FL: disruption of FOX TF family near the BCL6 promoter may result in reduced BCL6 expression, which then increases BCL2 expression over that caused by BCL2 gene translocation.
|
28765546 |
2017 |
Lymphoma, Follicular
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our findings evidence a positive correlation between SIRT1 and BCL6 expression increase in FL.
|
28324774 |
2017 |
Lymphoma, Follicular
|
0.400 |
Biomarker
|
disease |
BEFREE |
Compared to CD10<sup>+</sup> GI-FL, CD10<sup>down</sup> GI-FL significantly involved the stomach or large intestine (P = 0.015), and additionally showed the downexpression of BCL6 (P < 0.001).
|
27513891 |
2016 |
Lymphoma, Follicular
|
0.400 |
Biomarker
|
disease |
BEFREE |
We present here a unique case of follicular lymphoma (FL) with rearranged BCL2, BCL6, and BCL1 (also known as CCND1) genes.
|
25953460 |
2015 |
Lymphoma, Follicular
|
0.400 |
Biomarker
|
disease |
BEFREE |
Numerous microRNAs were found to be differentially expressed between FL(BCL2+/BCL6+) and FL(BCL2-/BCL6+), as well as diffuse FL, when compared to typical cases of FL.
|
24778012 |
2014 |
Lymphoma, Follicular
|
0.400 |
Biomarker
|
disease |
BEFREE |
Of the cases of FL (all CD10 and/or BCL-6 positive), 8 (80%) were positive for both HGAL and LMO2.
|
22914613 |
2013 |
Lymphoma, Follicular
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The use of three distinct anti-bcl-2 antibodies together with CD10 expression data and FISH analysis for bcl-2 and bcl-6 rearrangements allowed subclassification of follicular lymphoma into four distinct subgroups: (i) CD10-positive/bcl-2-positive, (ii) CD10-positive/bcl-2-negative, (iii) CD10-negative/bcl-2-positive, and (iv) CD10-negative/bcl-2-negative.All cases were bcl-6-positive.
|
23509938 |
2013 |
Lymphoma, Follicular
|
0.400 |
Biomarker
|
disease |
BEFREE |
All BCL6 translocations occurred in high-grade FL, and this suggests that FL carrying BCL6 translocation probably constitute a special biological subtype.
|
22968395 |
2012 |
Lymphoma, Follicular
|
0.400 |
FusionGene
|
disease |
ORPHANET |
All BCL6 translocations occurred in high-grade FL, and this suggests that FL carrying BCL6 translocation probably constitute a special biological subtype.
|
22968395 |
2012 |
Lymphoma, Follicular
|
0.400 |
Biomarker
|
disease |
BEFREE |
In our series, BCL-6 breaks were infrequent in BCL-2-negative follicular lymphoma.
|
21855110 |
2012 |
Lymphoma, Follicular
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Translocations affecting BCL2 and BCL6 genes are rare in grade 3B follicular lymphomas (2/23, 9% and 4/23, 17%) when compared with grade 1 or 2 follicular lymphomas (22/25, 88%, P<0.001 and 0/25, P<0.05), FL/LCC (7/9, 78%, P<0.001 and 2/9, 22%), grade 3A follicular lymphomas (7/12, 58%, P<0.01 and 2/12, 17%), unclassified grade 3 follicular lymphomas (6/15, 40% and 2/15, 13%) and diffuse large B-cell lymphoma/follicular lymphoma grade 3B (2/16, 13% and 8/16, 50%, P<0.05).
|
21659362 |
2011 |
Lymphoma, Follicular
|
0.400 |
Biomarker
|
disease |
BEFREE |
We studied the efficacy of 2 germinal center B-cell markers, HGAL and LMO2, in the separation of lymphomas derived from small B cells, particularly follicular lymphoma (FL) and marginal zone lymphoma occurring in nodal, extranodal, splenic, and bone marrow sites using immunohistochemical analysis for CD10, BCL6, BCL2, HGAL, and LMO2.
|
21502424 |
2011 |
Lymphoma, Follicular
|
0.400 |
Biomarker
|
disease |
BEFREE |
BCL6-mediated suppression of BCL2 is lost in FL and DLBCL, where the 2 proteins are pathologically coexpressed, because of BCL2 chromosomal translocations and other mechanisms, including Miz1 deregulation and somatic mutations in the BCL2 promoter region.
|
19549844 |
2009 |
Lymphoma, Follicular
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
BCL6 rearrangements were found in all grades of follicular lymphoma but were most frequent in grade 3 t(14;18)-negative follicular lymphoma (60%).
|
19465899 |
2009 |
Lymphoma, Follicular
|
0.400 |
Biomarker
|
disease |
BEFREE |
BCL2- and BCL6-translocations correlate with particular phenotypes of follicular lymphomas.
|
20032416 |
2009 |
Lymphoma, Follicular
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To test the association of SHM with transformation of follicular lymphoma (FL), we sequenced mutational hot spots in five proto-oncogenes (BCL6, PAX5, RHOH, MYC and PIM1) in 32 low-grade FL (lgFL) with follicular histology and 26 transformed FL (tFL) with diffuse large cell histology.
|
18180034 |
2008 |
Lymphoma, Follicular
|
0.400 |
Biomarker
|
disease |
LHGDN |
BCL6 gene aberration, especially amplification/3q27 gain, indicates the presence of certain morphological and phenotypical findings in follicular lymphoma cases without IGH/BCL2 rearrangement.
|
18500267 |
2008 |
Lymphoma, Follicular
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our data confirm the presence of a relationship between histological grade and translocation status, suggesting that FLs carrying BCL6 translocations probably constitute a special biological subtype.
|
18203018 |
2008 |